Display options
Cite
Masse MH, Adhikari NKJ, Théroux X, et al. The evolution of mean arterial pressure in critically ill patients on vasopressors before and during a trial comparing a specific mean arterial pressure target to usual care. BMC Anesthesiol. 2022;22(1):6doi: 10.1186/s12871-021-01529-w.
Masse, M. H., Adhikari, N. K. J., Théroux, X., Battista, M. C., D'Aragon, F., Pinto, R., Cohen, A., Mayette, M., St-Arnaud, C., Kho, M., Chassé, M., Lebrasseur, M., Watpool, I., Porteous, R., Wilcox, M. E., & Lamontagne, F. (2022). The evolution of mean arterial pressure in critically ill patients on vasopressors before and during a trial comparing a specific mean arterial pressure target to usual care. BMC anesthesiology, 22(1), 6. https://doi.org/10.1186/s12871-021-01529-w
Masse, Marie-Hélène, et al. "The evolution of mean arterial pressure in critically ill patients on vasopressors before and during a trial comparing a specific mean arterial pressure target to usual care." BMC anesthesiology vol. 22,1 (2022): 6. doi: https://doi.org/10.1186/s12871-021-01529-w
Masse MH, Adhikari NKJ, Théroux X, Battista MC, D'Aragon F, Pinto R, Cohen A, Mayette M, St-Arnaud C, Kho M, Chassé M, Lebrasseur M, Watpool I, Porteous R, Wilcox ME, Lamontagne F. The evolution of mean arterial pressure in critically ill patients on vasopressors before and during a trial comparing a specific mean arterial pressure target to usual care. BMC Anesthesiol. 2022 Jan 03;22(1):6. doi: 10.1186/s12871-021-01529-w. PMID: 34979938.
Copy Download .nbib Format: NLM
Share it on

BMC Anesthesiol. 2022 Jan 03;22(1):6. doi: 10.1186/s12871-021-01529-w.

The evolution of mean arterial pressure in critically ill patients on vasopressors before and during a trial comparing a specific mean arterial pressure target to usual care.

BMC anesthesiology

Marie-Hélène Masse, Neill K J Adhikari, Xavier Théroux, Marie-Claude Battista, Frédérick D'Aragon, Ruxandra Pinto, Alan Cohen, Michaël Mayette, Charles St-Arnaud, Michelle Kho, Michaël Chassé, Martine Lebrasseur, Irene Watpool, Rebecca Porteous, M Elizabeth Wilcox, François Lamontagne

Affiliations

  1. Faculty of Medicine and Health Sciences, Université de Sherbrooke, 12e Avenue Nord, Sherbrooke, Québec, J1H 5N4, Canada.
  2. Interdepartmental Division of Critical Care Medicine, University of Toronto, 209 Victoria Street, Toronto, Ontario, M5B 1T8, Canada.
  3. Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
  4. Faculty of Health Sciences, School of Rehabilitation Science, Institute of Applied Health Sciences, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4L8, Canada.
  5. Department of Medicine, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, Québec, H3T 1J4, Canada.
  6. Centre de recherche, Centre hospitalier de l'Université de Montréal, 900 rue Saint-Denis, Montréal, Québec, H2X 0A9, Canada.
  7. Ottawa Hospital Research Institute, 1053 Carling Ave, Ottawa, Ontario, K1Y 4E9, Canada.
  8. Faculty of Medicine and Health Sciences, Université de Sherbrooke, 12e Avenue Nord, Sherbrooke, Québec, J1H 5N4, Canada. [email protected].

PMID: 34979938 DOI: 10.1186/s12871-021-01529-w

Abstract

BACKGROUND: In randomized clinical controlled trials, the choice of usual care as the comparator may be associated with better clinician uptake of the study protocol and lead to more generalizable results. However, if care processes evolve to resemble the intervention during the course of a trial, differences between the intervention group and usual care control group may narrow. We evaluated the effect on mean arterial pressure of an unblinded trial comparing a lower mean arterial pressure target to reduce vasopressor exposure, vs. a clinician-selected mean arterial pressure target, in critically ill patients at least 65 years old.

METHODS: For this multicenter observational study using data collected both prospectively and retrospectively, patients were recruited from five of the seven trial sites. We compared the mean arterial pressure of patients receiving vasopressors, who met or would have met trial eligibility criteria, from two periods: [1] at least 1 month before the trial started, and [2] during the trial period and randomized to usual care, or not enrolled in the trial.

RESULTS: We included 200 patients treated before and 229 after trial initiation. There were no differences in age (mean 74.5 vs. 75.2 years; p = 0.28), baseline Acute Physiology and Chronic Health Evaluation II score (median 26 vs. 26; p = 0.47) or history of chronic hypertension (n = 126 [63.0%] vs. n = 153 [66.8%]; p = 0.41). Mean of the mean arterial pressure was similar between the two periods (72.5 vs. 72.4 mmHg; p = 0.76).

CONCLUSIONS: The initiation of a trial of a prescribed lower mean arterial pressure target, compared to a usual clinician-selected target, was not associated with a change in mean arterial pressure, reflecting stability in the net effect of usual clinician practices over time. Comparing prior and concurrent control groups may alleviate concerns regarding drift in usual practices over the course of a trial or permit quantification of any change.

© 2021. The Author(s).

Keywords: Arterial pressure; Control groups; Critical care; Research design; Vasoconstrictor agents

References

  1. Silverman HJ, Miller FG. Control group selection in critical care randomized controlled trials evaluating interventional strategies: an ethical assessment. Crit Care Med. 2004;32(3):852–7. - PubMed
  2. Thompson BT, Schoenfeld D. Usual care as the control group in clinical trials of nonpharmacologic interventions. Proc Am Thorac Soc. 2007;4(7):577–82. - PubMed
  3. Angriman F, Masse MH, Adhikari NKJ. Defining standard of practice: pros and cons of the usual care arm. Curr Opin Crit Care. 2019;25(5):498–504. - PubMed
  4. Deans KJ, Minneci PC, Danner RL, Eichacker PQ, Natanson C. Practice misalignments in randomized controlled trials: identification, impact, and potential solutions. Anesth Analg. 2010;111(2):444–50. - PubMed
  5. Times N. Trial by Fire: Critics Demand That Huge Sepsis Study Be Stopped. 2018. [Available from: https://www.nytimes.com/2018/09/24/health/sepsis-trial-treatments.html . - PubMed
  6. Takala J. Better conduct of clinical trials: the control group in critical care trials. Crit Care Med. 2009;37(1 Suppl):S80–90. - PubMed
  7. Lantos JD, Feudtner C. SUPPORT and the ethics of study implementation: lessons for comparative effectiveness research from the trial of oxygen therapy for premature babies. Hast Cent Rep. 2015;45(1):30–40. - PubMed
  8. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian critical care trials group. N Engl J Med. 1999;340(6):409–17. - PubMed
  9. Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–8. - PubMed
  10. Arch JJ, Stanton AL. Examining the “usual” in usual care: a critical review and recommendations for usual care conditions in psycho-oncology. Support Care Cancer. 2019;27(5):1591–600. - PubMed
  11. Masse MH, Battista MC, Wilcox ME, Pinto R, Marinoff N, D'Aragon F, et al. Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial. BMJ Open. 2020;10(11):e037947. - PubMed
  12. Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, Grieve RD, et al. Effect of reduced exposure to vasopressors on 90-Day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. JAMA. 2020;323:938–49. - PubMed
  13. Lamontagne F, Cook DJ, Meade MO, Seely A, Day AG, Charbonney E, et al. Vasopressor use for severe hypotension-a multicentre prospective observational study. PLoS One. 2017;12(1):e0167840. - PubMed
  14. Andreis DT, Singer M. Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med. 2016;42(9):1387–97. - PubMed
  15. Khanna A, Ostermann M, Bellomo R. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(26):2604. - PubMed
  16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–29. - PubMed
  17. Disease K. Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138. - PubMed
  18. Kwak SG, Kim JH. Central limit theorem: the cornerstone of modern statistics. Korean J Anesthesiol. 2017;70(2):144–56. - PubMed
  19. Byrt T. How good is that agreement? Epidemiology. 1996;7(5):561. - PubMed
  20. St-Arnaud C, Ethier JF, Hamielec C, Bersten A, Guyatt G, Meade M, et al. Prescribed targets for titration of vasopressors in septic shock: a retrospective cohort study. CMAJ Open. 2013;1(4):E127–33. - PubMed

Publication Types